Developer of an imaging system designed to improve patient outcomes at a reduced cost by applying artificial intelligence to vascular diagnostic imaging. Elucid Bioimaging is based in Boston, MA. It was valued at $288 million at its later-stage round in Oct 2025, the last priced event on record. It has raised $163 million across 3 recorded rounds; the latest was a $36.5 million early-stage round in Oct 2025.
PMV mark · valuation
$288.0M
Oct 2026
Priced at
its later-stage round
Oct 2025
Total raised
$163.2M
Last round
Early Stage VC
Oct 2025
No prints on record
No secondary trades in Elucid Bioimaging shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Elucid Bioimaging with a free account
·The complete investor list: 24 names
·Watch Elucid Bioimaging: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Elucid Bioimaging stock.
